| 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative D Aletaha, T Neogi, AJ Silman, J Funovits, DT Felson, CO Bingham III, ... Arthritis & rheumatism 62 (9), 2569-2581, 2010 | 14584 | 2010 |
| Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA) M Dougados, M Soubrier, A Antunez, P Balint, A Balsa, MH Buch, ... Annals of the rheumatic diseases 73 (1), 62-68, 2014 | 1003 | 2014 |
| Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind … JS Smolen, J Kay, MK Doyle, R Landewé, EL Matteson, J Wollenhaupt, ... The Lancet 374 (9685), 210-221, 2009 | 700 | 2009 |
| ACR/EULAR 2010 rheumatoid arthritis classification criteria J Kay, KS Upchurch Rheumatology 51 (suppl_6), vi5-vi9, 2012 | 664 | 2012 |
| Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double‐blind, placebo‐controlled, dose‐ranging study J Kay, EL Matteson, B Dasgupta, P Nash, P Durez, S Hall, EC Hsia, J Han, ... Arthritis & Rheumatism 58 (4), 964-975, 2008 | 385 | 2008 |
| The role of interleukin-1 in the pathogenesis of rheumatoid arthritis J Kay, L Calabrese Rheumatology 43 (suppl_3), iii2-iii9, 2004 | 363 | 2004 |
| The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: phase 2 methodological report T Neogi, D Aletaha, AJ Silman, RL Naden, DT Felson, R Aggarwal, ... Arthritis & Rheumatism 62 (9), 2582-2591, 2010 | 361 | 2010 |
| Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex. T Matsuyama, A Yamada, J Kay, KM Yamada, SK Akiyama, ... The Journal of experimental medicine 170 (4), 1133-1148, 1989 | 359 | 1989 |
| The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I J Funovits, D Aletaha, V Bykerk, B Combe, M Dougados, P Emery, ... Annals of the rheumatic diseases 69 (9), 1589-1595, 2010 | 285 | 2010 |
| Isolation and characterization of beta-glucan receptors on human mononuclear phagocytes. JK Czop, J Kay The Journal of experimental medicine 173 (6), 1511-1520, 1991 | 269 | 1991 |
| Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention S Karmakar, J Kay, EM Gravallese Rheumatic Disease Clinics 36 (2), 385-404, 2010 | 263 | 2010 |
| Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure DJ Todd, A Kagan, LB Chibnik, J Kay Arthritis & Rheumatism: Official Journal of the American College of …, 2007 | 242 | 2007 |
| Evolution of treatment for rheumatoid arthritis KS Upchurch, J Kay Rheumatology 51 (suppl_6), vi28-vi36, 2012 | 230 | 2012 |
| The changing landscape of biosimilars in rheumatology T Dörner, V Strand, P Cornes, J Gonçalves, L Gulácsi, J Kay, TK Kvien, ... Annals of the rheumatic diseases 75 (6), 974-982, 2016 | 221 | 2016 |
| Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases J Kay, MM Schoels, T Dörner, P Emery, TK Kvien, JS Smolen, ... Annals of the Rheumatic Diseases 77 (2), 165-174, 2018 | 216 | 2018 |
| Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial GR Burmester, WF Rigby, RF van Vollenhoven, J Kay, A Rubbert-Roth, ... Annals of the rheumatic diseases 75 (6), 1081-1091, 2016 | 212 | 2016 |
| Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations M Girardi, J Kay, DM Elston, PE LeBoit, A Abu-Alfa, SE Cowper Journal of the American Academy of Dermatology 65 (6), 1095-1106. e7, 2011 | 182 | 2011 |
| Imatinib mesylate treatment of nephrogenic systemic fibrosis J Kay, WA High Arthritis & Rheumatism: Official Journal of the American College of …, 2008 | 175 | 2008 |
| Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines Y Wang, TK Alkasab, O Narin, RM Nazarian, R Kaewlai, J Kay, ... Radiology 260 (1), 105-111, 2011 | 170 | 2011 |
| Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN) J Sieper, J Braun, J Kay, S Badalamenti, AR Radin, L Jiao, S Fiore, ... Annals of the Rheumatic Diseases 74 (6), 1051-1057, 2015 | 167 | 2015 |
